Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead’s Novel Integrase Inhibitor Could Enter Phase III In Second Half

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm reports first-quarter revenues of over $1 billion.

You may also be interested in...



Gilead’s Elvitegravir Phase III Could Face Challenges With Novel HIV Comparator

Integrase inhibitor will likely need to be compared to active control such as investigational maraviroc or raltegravir in Phase III, firm reports.

Gilead’s Elvitegravir Phase III Could Face Challenges With Novel HIV Comparator

Integrase inhibitor will likely need to be compared to active control such as investigational maraviroc or raltegravir in Phase III, firm reports.

Merck’s Novel HIV Drug Isentress Granted Six-Month FDA Review

First-in-class integrase inhibitor could see a mid-October approval.

Related Content

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel